timothy sykes logo

Stock News

RAPT Therapeutics Gains After Piper Sandler’s Favorable Review

Jack KelloggAvatar
Written by Jack Kellogg Reviewed by Tim Sykes Fact-checked by Ellis Hobbs
Updated 1/20/2026, 11:33 am ET 1/20/2026, 11:33 am ET | 4 min 4 min read
RAPT Therapeutics Gains After Piper Sandler’s Favorable Review Thumbnail

RAPT Therapeutics Inc.’s stocks have been trading up by 63.89 percent amid positive sentiment and promising developments.

  • Future presentation at 44th Annual J.P. Morgan Healthcare Conference positions RAPT as a frontrunner in novel therapies for inflammatory diseases.

Candlestick Chart

Live Update At 11:32:46 EST: On Tuesday, January 20, 2026 RAPT Therapeutics Inc. stock [NASDAQ: RAPT] is trending up by 63.89%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

In recent trading sessions, RAPT Therapeutics’ stock made significant strides. Opening at $57.47, it saw slight fluctuations before closing at $57.525. The stock’s rise signals firm investor confidence stemming from Piper Sandler’s assessment. Such evaluations can drastically sway RAPT’s financial landscape, pushing shares upwards even amidst varied market conditions.

Examining RAPT’s financial strength paints a picture of potential resilience. With total assets reported at approximately $165.74M and a strong current ratio of 12, the company’s foundation seems robust. However, challenges persist. Revenue declines over the last five years indicate areas of concern. Notably, the negative 6995.3 pre-tax profit margin underscores potential financial strain. Yet, strategic advancements and investment in R&D may offset some economic shortfalls.

Confidence in the Market

Piper Sandler’s assessment, deeming RAPT “Overweight”, offers optimism. By identifying ozureprubart’s clinical security through connections with Xolair, the investment bank fuels expectations of increased market traction. Such endorsements often lead to market enthusiasm, which has seemingly catalyzed the stock’s recent rise. Predictions showing a potential climb to $95 offer promising outlooks for both loyal investors and emerging ones.

More Breaking News

However, it’s essential to juxtapose this enthusiasm with RAPT’s existing vulnerabilities. Based on financial reports, operational costs remain high, and earnings per share last reported at a loss of $0.65. These elements can temper some optimistic projections, suggesting a balanced outlook is warranted.

Looking Ahead: The Road to Recovery or Further Challenges?

Positioned in the upcoming J.P. Morgan Healthcare Conference, RAPT Therapeutics plans to showcase its commitment to pioneering treatments for immune-related ailments. This stage offers an invaluable chance to spotlight solutions and possibly attract broader investments. Such events serve as crucial junctions, providing companies like RAPT an opportunity to pivot from merely promising to delivering tangible results.

With assets showing minor depreciation and a debt-to-equity ratio at 0.02, the financial footing appears somewhat stable. Yet, the negative figures in profitability margins remain a concern. It’s a story of potential, overshadowed by pressing challenges, with significant speculation about RAPT’s market stance.

Conclusion

The forecasts surrounding RAPT Therapeutics blend optimism with caution. Trading circles have awakened to the prospect of favorable returns, thanks to Piper Sandler’s endorsement. However, underlying financial constraints and market variables remain. As millionaire penny stock trader and teacher Tim Sykes, says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” Observing how RAPT navigates forthcoming financial disclosures and market introductions will be pivotal in predicting both short-term stock shifts and long-term stability. With a strategic approach and timely execution, RAPT still holds considerable promise despite past hurdles.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Jack Kellogg

He teaches webinars on Tim Sykes’ Trading Challenge He became Tim’s youngest millionaire student in 2020. Now he’s second on the Trading Challenge leaderboard with $12.9 million in career earnings. He’s a master of the 7-Step Pennystocking Framework. Jack is one of a rare breed of traders to profitably trade the entire penny stock framework.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”